JAZZ - Company ID 0001232524
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $4.27B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $4.27B | +4.9% |
| FY 2024 | $4.07B | +6.1% |
| FY 2023 | $3.83B | +4.8% |
| FY 2022 | $3.66B | +18.3% |
| FY 2021 | $3.09B | +30.9% |
| FY 2020 | $2.36B | +9.3% |
| FY 2019 | $2.16B | +14.3% |
| FY 2018 | $1.89B | +16.8% |
| FY 2017 |
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $4.27B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Jazz Pharmaceuticals plc's revenue grew from $272.28M to $4.27B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.62B |
| +8.8% |
| FY 2016 | $1.49B | +12.3% |
| FY 2015 | $1.32B | +13.0% |
| FY 2014 | $1.17B | +34.4% |
| FY 2013 | $872.42M | +48.9% |
| FY 2012 | $585.98M | +115.2% |
| FY 2011 | $272.28M | - |